Table 2.
Clinical characteristics of patients with systemic sclerosis
| Patients with SSc (n = 45) | |
|---|---|
| Diffuse/limited cutaneous subtype | 16 (35.6%)/29 (64.4%) |
| Anti-centromere/anti-topoisomerase I | 21 (46.7%)/19 (42.2%) |
| Disease duration ≤3 years/˃3 years | 15 (34.1%)/29 (65.9%) |
| Medsger severity scale | |
| Grades 0, 1 and 2 | 1 (2.2%), 14 (31.1%) and 7 (15.6%) |
| Grades 3 and 4 | 22 (48.9%) and 1 (2.2%) |
| Pitting scars | 24 (53.3%) |
| Digital ulcers | 18 (40.0%) |
| Digital gangrene | 4 (8.9%) |
| Telangiectasia | 29 (64.4%) |
| Pulmonary function tests | |
| DLCO, % | 97.3 [88.8–103.5] |
| DLCO/VA, % | 67.4 [61.35–78.2] |
| FVC, % | 99.3 [84.1–115.6] |
| Pulmonary fibrosis | 7 (18.9%) |
| Systolic pulmonary arterial pressurea | 33 [27.8–37.5] |
DLCO Diffusing capacity of the lung for carbon monoxide, FVC Forced vital capacity, VA alveolar volume
Qualitative variables are described using counts and percentages. Quantitative variables are described using median [first quartile–third quartile]
aTransthoracic echocardiography assessment